AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01461850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy + Interval Debulking Surgery
Description: Patients with suspected advanced ovarian cancer (FIGO stage IIIC) will undergo only to diagnostic laparoscopy. Omental cake, diaphragmatic or peritoneal extensive carcinomatosis, tumor diffusion to the small and large curvature of the stomach, large and/or small bowel mesentery disease, spleen and/or liver metastases will be investigated in order to obtain a laparoscopic score. After neoadjuvant chemotherapy interval debulking surgery will be performed: total hysterectomy, bilateral salpingo-oophorectomy, radical omentectomy, appendectomy, pelvic and paraaortic lymphadenectomy, eventual bowel resection, eventual bladder resection, eventual splenectomy, eventual parietal and diaphragmatic peritonectomy, eventual gastric resection, eventual hepatic resection, eventual pancreas resection, eventual cholecystectomy.
Study NCT01461850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary Debulking Surgery + Adjuvant Chemotherapy
Description: Patients with suspected advanced ovarian cancer (FIGO stage IIIC) will undergo to diagnostic laparoscopy. Omental cake, diaphragmatic or peritoneal extensive carcinomatosis, tumor diffusion to the small and large curvature of the stomach, large and/or small bowel mesentery disease, spleen and/or liver metastases will be investigated in order to obtain a laparoscopic score. Then, an attempt of laparotomic cytoreduction will be performed: total hysterectomy, bilateral salpingo-oophorectomy, radical omentectomy, appendectomy, pelvic and paraaortic lymphadenectomy, eventual bowel resection, eventual bladder resection, eventual splenectomy, eventual parietal and diaphragmatic peritonectomy, eventual gastric resection, eventual hepatic resection, eventual pancreas resection, eventual cholecystectomy.
Study NCT01416246 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractionated Stem Cell Infusions
Description: Following enrollment patients will be treated with melphalan intravenously (IV) through a central venous catheter (CVC) over 30 minutes at 200mg/m2 or 140mg/m2 (if creatinine clearance is \< or = to 50 and/or age > 70 years) on day -2. Following 24 hours of rest, the first dose of CD34+ stem cell will be administered on day 0 (2.5-5 x 106 CD 34+ stem cells/kg)+/- 0.5 x 106 CD34+ stem cells/kg), followed by 3 additional doses of CD 34+ stem cells (1.5-2.5 x 106 CD 34+ stem cells/kg)+/- 0.5 x 106 CD34+ stem cells/kg) on days +2, +4, and +6. Pegfilgrastim 6μg will be administered on day +1. Filgrastim 5μg/kg will be 12-24 hours after the 2nd-4th stem cell infusions. There will be a +/- 1 day window for the Day +2, +4, and +6 infusions to accommodate infusions that occur over the weekend or on holidays.
Study NCT05034653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: During fasting day, no food or drink allowed from dawn to dusk
Study NCT05034653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Plate
Description: Quarter-quarter-half meal concept
Study NCT05034653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Plate
Description: Quarter-quarter-half meal concept
Study NCT04634305 — intervention group
Intervention type: PROCEDURE
Intervention: Total elbow arthroplasty
Description: Total elbow arthroplasty by a single operator
Study NCT04471285 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: acupuncture
Study NCT04439539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 injection will be administered subcutaneously.
Study NCT04439539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN-alpha-2a
Description: PegIFN-alpha-2a injection will be administered subcutaneously.
Study NCT04439539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil
Description: Tenofovir disoproxil film-coated tablet will be administered orally.
Study NCT04471285 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Sham acupuncture
Study NCT03995329 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IQOS
Description: Acute effects of IQOS on pulmonary function, oxygen saturation, exhaled CO, heart rate and arterial blood pressure.
Study NCT01604356 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Description: Ten treatment sessions at our center during a two week period (5 sessions per week). Each session will last approximately 30 minutes. The intervention will involve the placement of acupuncture needles in a standard set of points across all patients, located on the head, around the eyes, on the abdomen, on the hands, feet, arms and legs. An electro-acupuncture device \[Transcutaneous electrical nerve stimulator (TENS) unit by Lhasa OMS Inc.; model AWQ-104L\] and will be used on four of the acupuncture points (two per session) located on the forehead, and side of the face/temple.
Study NCT03685890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: One infusion of nivolumab (Opdivo®) 480mg (flat dose) in NaCl (Natriumklorid Baxter Viaflo, 9 mg/ml) during 60 minutes
Study NCT03685890 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Isolated limb perfusion (ILP)
Description: Patients will be treated with ILP according to clinical routine at each separate site. The procedure is performed under general anaesthesia. The major artery and vein of the limb is catheterized, and a tourniquet is placed proximally on the limb. Continuous leakage monitoring is performed. The perfusate is heated to 40C and after ensuring steady state, melphalan (Alkeran®) at a dose of 13 mg/L (upper limb) or 10 mg/L (lower limb) is infused into the circulation during 20 minutes for a total perfusion time of 60 minutes. According to local routine tasonermin (Beromun®) will be added to the perfusate 30 minutes before the melphalan as a bolus dose of 1-4 mg.
Study NCT03685890 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Isolated limb perfusion (ILP)
Description: Patients will be treated with ILP according to clinical routine at each separate site. The procedure is performed under general anaesthesia. The major artery and vein of the limb is catheterized, and a tourniquet is placed proximally on the limb. Continuous leakage monitoring is performed. The perfusate is heated to 40C and after ensuring steady state, melphalan (Alkeran®) at a dose of 13 mg/L (upper limb) or 10 mg/L (lower limb) is infused into the circulation during 20 minutes for a total perfusion time of 60 minutes. According to local routine tasonermin (Beromun®) will be added to the perfusate 30 minutes before the melphalan as a bolus dose of 1-4 mg.
Study NCT03077087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thin Integra® (125 cm2)
Description: 125 cm2 represents approximately 0.7% of an average sized patient's total body surface area. The remaining injury areas would be covered with standard-thickness Integra® only. The donor graft, a 4 cm x 10 cm sheet of skin, would be meshed in a 3:1 ratio to be expanded to cover the 125 cm2 sheet of thin Integra®. The patient's post-operative care would be largely unchanged, although the patient would have a donor site of 40 cm2 that would be dressed and managed in the usual fashion.
Study NCT04620798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate vs. delayed provision of antibody test results
Description: The primary experiment will be assessing whether provision of the antibody test results leads to behavior change with respect to personal protective behaviors. To that end, we will randomize all participants to a trial arm that immediately receive results (within 24 hours) or a trial arm with a delayed provision of results (after 4 weeks).
Study NCT03545971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310
Description: IBI310 is anti CTLA-4 antibody
Study NCT04439539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide
Description: Tenofovir alafenamide film-coated tablet will be administered orally.
Study NCT04439539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: JNJ-56136379 will be administered orally.
Study NCT00874237 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled loxapine
Description: Inhaled Staccato Loxapine 10 mg single dose
Study NCT00638937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Description: Given PO
Study NCT02586714 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Observation only
Study NCT00874237 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled placebo
Description: Inhaled Staccato placebo single dose
Study NCT00874237 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oral moxifloxacin
Description: Oral moxifloxacin 400 mg
Study NCT00874237 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oral placebo
Description: Oral placebo similar in appearance to moxifloxacin 400 mg
Study NCT04003090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicoline
Description: After treatment with a solution containing citicoline 1% eye-drops, 0.2% high molecular weight hyaluronic acid and 0.01% benzalkonium chloride patients underwent a 23G standard 3-port pars plana vitrectomy. The vitreous sample was taken at the beginning of the surgery and then analyzed.
Study NCT03991026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy food and Education/Cooking Classes
Description: The intervention includes providing weekly seasonal produce and healthy foods to participants in addition to an education/cooking class that will be tailored to Diabetes Mellitus, Type II.
Study NCT03585855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MSC transplantation
Description: MSC transplantation: patients with ABMR treated with MSC transplantation
Study NCT00792298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: oral tablet taken before bedtime
Study NCT00792298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-matched Placebo to Suvorexant
Description: Dose-matched placebo to suvorexant taken before bedtime (oral tablet)
Study NCT06091644 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AirAngel® 3D printed videolaryngoscope
Description: This is a mannequin study that aims to compare a videolaryngoscope produced with 3D printing with a Storz videolaryngoscope and a Macintosh direct laryngoscope in the hands of inexperienced users in terms of ease of use, glottic imaging and intubation success.
Study NCT01590342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Diclofenac 75 mg, two doses
Study NCT01590342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, two doses
Study NCT04093648 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: TEGAR T cells
Description: Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:DL1: 1x10\^7/m2 DL2: 3x10\^7/m2 DL3: 1x10\^8/m2 DL4: 3x10\^8/m2 DL5: 1x10\^9/m2 If DLTs are observed on DL1, patients will be enrolled on DL0 at 3x10\^6/m2 dose.~The first patient on each dose level has to be 28 days post-CAR T cell infusion before the second patient can be enrolled. The doses are calculated according to the actual number of GPC3-CAR transduced T cells.
Study NCT04093648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously
Study NCT04093648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously
Study NCT01766947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensimed Triggerfish
Description: Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
Study NCT01551693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA-9090
Study NCT04280432 — intervention group
Intervention type: PROCEDURE
Intervention: CESAREAN
Description: Women hospitalized for cesarean section
Study NCT03093155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixabepilone
Description: Ixabepilone will be administered at 20 mg/m2 intravenously days 1, 8, 15 of a 28-day cycle over one hour.~Treatment will continue until progression, death, or prohibitive side effects. If any patient has a complete response, patient may stop treatment after 2 additional consolidation cycles following documented complete response
Study NCT03093155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Ixabepilone will be administered at 20 mg/m2 intravenously days 1, 8, 15 of a 28-day cycle over one hour.~Treatment will continue until progression, death, or prohibitive side effects. If any patient has a complete response, patient may stop treatment after 2 additional consolidation cycles following documented complete response
Study NCT03093155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at 10 mg/kg intravenously days 1, 15 of a 28-day cycle over one hour. Bevacizumab will be infused after ixabepilone. The first dose of bevacizumab will be administered intravenously over 90 minutes; the second dose may be administered over 60 minutes if no prior reaction to previous infusion; subsequent doses may be administered over 30 minutes if no prior reaction to previous infusion.~Treatment will continue until progression, death, or prohibitive side effects. If any patient has a complete response, patient may stop treatment after 2 additional consolidation cycles following documented complete response.
Study NCT02310620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: regular playing with the logic games developed in the framework of the M3W (Mental Wellness Toolset) project (https://m3w-project.eu/)
Study NCT02504554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral Vancomycin
Description: an antibiotic
Study NCT02504554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MoviPrep
Description: a bowel cleanse
Study NCT02504554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilosec
Description: a stomach acid suppressan
Study NCT02504554 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human fecal material; processed, frozen administered orally
Description: human fecal material; processed, frozen, administered orally
Study NCT02504554 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human fecal material; processed, frozen; administered orally and rectally
Description: human fecal material; processed, frozen; administered orally and rectally
Study NCT01567644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)
Description: Energy Density - 0.09 mJ/mm2
Study NCT04456829 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol drink
Description: Subjects will consume a bottle of resveratrol drink for two months.
Study NCT04456829 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Subjects will consume a bottle of placebo drink for two months.
Study NCT02159144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold stress
Study NCT04531475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X842
Description: X842 capsules
Study NCT04531475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X842 Placebo
Description: X842 placebo-matching capsules
Study NCT04531475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole capsules
Study NCT04531475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole Placebo
Description: Lansoprazole placebo-matching capsules
Study NCT03545971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: PD-1 monoclonal antibody
Study NCT02052713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg
Description: Commercially available, orange and brown, hard shell capsule, administered orally as a single dose on Day 1 under fasted condition.
Study NCT04134494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablative Fractional 2940 nm Laser
Description: * Treatment visit 1, month 0: On the first pass, the depth of the laser will be from 300 to 500 microns, or the thickness of 3 to 5 sheets of paper; the depth will be based on the biopsy that was used to diagnosis the lichen sclerosus. On the second pass, the depth will be 50 microns deeper than the first pass and the hand piece rotated 45˚.~* Treatment visit 2, month 1: The first pass of the laser will be the same depth as the second pass from the last visit. The second pass will be 50 microns deeper and the hand piece rotated 45˚.~* Treatment visit 3, month 2: The first pass of the laser will be the same depth as the second pass from the last visit. The second pass will be 50 microns deeper and the hand piece rotated 45˚.
Study NCT02221544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-frequency repetitive Transcranial Magnetic Stimulation
Description: Participants will receive treatment at a frequency of 3 sessions per week for 4 weeks (12 sessions). In each session patient will receive repetitive Transcranial Magnetic Stimulation using a stimulation frequency of 10 Hz for half an hour.~The treatment is done by attaching an electromagnetic coil to the scalp using a special hat. Each patient has a personal hat which serves him throughout the entire process. The treatment is performed without anesthesia and patient fully conscious. During the treatment he sits comfortably on a chair, meanwhile the magnetic field passes through the skull into the brain.
Study NCT02221544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS maintenance
Description: Same treatment as in rTMS treatment intervention, but only once a week for a month
Study NCT02221544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Participants will receive sham treatment at a frequency of 3 sessions per week for 4 weeks (12 sessions total) for half an hour each session. The treatment is done by attaching an electromagnetic coil to the scalp but without turning on the magnetic field.
Study NCT02221544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham maintenance
Description: The same as Sham stimuli intervention, but once a week for a month
Study NCT00035451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azimilide Dihydrochloride
Description: 125 mg azimilide tablets, twice a day for 6 months
Study NCT00035451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets, twice daily for 6 months
Study NCT00035451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotalol
Description: 160 mg sot twice daily for 6 months
Study NCT01618292 — intervention group
Intervention type: PROCEDURE
Intervention: Robotic sacral colpopexy
Description: Patients who underwent robotic assisted sacral colpopexy for the treatment of pelvic organ prolapse
Study NCT01140009 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Fluviral 2010/11 Tri-valent Seasonal Influenza vaccine
Description: Vaccination of .05mL of Fluviral vaccine will be injected once at either visit 1 or 2 depending upon randomization in the deltoid muscle of the non-dominant arm
Study NCT02052713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule
Description: Orange and brown, hard shell capsule, administered orally, as a single-dose on Day 1 under fasted condition.
Study NCT04382989 — intervention group
Intervention type: DEVICE
Intervention: Analysis of human milk composition by mid-infrared spectrophotometry
Description: Analysis of human milk macronutrient content was performed by mid-infrared spectrophotometry using a Miris Human Milk Analyser.~An immune-enzymatic ELISA assays were used to estimate lysozyme and lactoferrin concentrations in human milk.
Study NCT02894229 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Stress Reduction
Description: A modified version of traditional MBSR. The current study's version of MBSR is shortened to 6-weeks.
Study NCT02894229 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT) Group
Description: A 6-week, 2-hour per group, skills group that focuses on various cognitive-behavioral skills for stress reduction (e.g., progressive muscle relaxation; cognitive restructuring).
Study NCT02799108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS
Description: High-resolution EEG-fNIRS recording lasting a maximum of 30 minutes by using expressive and receptive language paradigms
Study NCT02799108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: fMRI acquisition under the same stimulation conditions
Study NCT00615069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 31 mm GORE EXCLUDER® AAA Endoprosthesis
Description: GORE EXCLUDER® AAA Endoprosthesis - 31 mm device implanted for the primary treatment of infrarenal abdominal aortic aneurysms (AAA)
Study NCT02435914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-223575 ophthalmic solution
Description: AGN-223575 ophthalmic solution once or twice daily
Study NCT02435914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-223575 vehicle ophthalmic solution
Description: Vehicle to AGN22375 ophthalmic solution once or twice daily.